Effects of naltrexone on alcohol self‐administration and craving: meta‐analysis of human laboratory studies
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Randomized clinical trials have established the efficacy of naltrexone for reducing quantity of alcohol consumption and incidence of relapse to heavy drinking. To evaluate putative treatment mechanisms, human laboratory studies have examined naltrexone's effects on alcohol responses and self‐administration during short‐term medication protocols. Results from these studies are inconsistent and have yet to be examined in aggregate. This meta‐analysis aimed to quantify naltrexone's effects on alcohol self‐administration and craving in the context of placebo‐controlled human laboratory trials. Potential moderators of medication effects were also examined. Meta‐analyses of alcohol self‐administration (k = 9, N = 490) and craving (k = 16, N = 748) confirmed that, under controlled experimental conditions, naltrexone reduces the quantity of consumption (Hedges' g = −.277, SE = .074, 95 percent CI = −.421, −.133, p < .001) and magnitude of self‐reported craving (g = −.286, SE = .066, 95 percent CI = −.416, −.156, p < .001) relative to placebo. Subgroup and moderation analyses found no evidence that effect sizes differed by study population (dependent versus non‐dependent drinkers), laboratory paradigm or duration of medication exposure. These results substantiate prior evidence for reductions in event‐level craving and consumption as potential treatment mediators, also establishing effect sizes to inform future human laboratory trials. From a clinical perspective, these results may provide additional evidence regarding naltrexone's efficacy in the context of acute or subacute dosing regimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Naltrexone in the Treatment of Alcohol Dependence
Volpicelli, J. R. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110040006 · Cited by 1,828
Jonas, D. E., Amick, H. R., Feltner, C., Bobashev, G., Thomas, K., Wines, R., Kim, M. M., Shanahan, E., Gass, C. E., Rowe, C. J., et al. (2014) · JAMA · doi:10.1001/jama.2014.3628 · Cited by 923
Heterogeneity of Alcohol Use Disorder: Understanding Mechanisms to Advance Personalized Treatment
Litten, R. Z., Ryan, M. L., Falk, D. E., Reilly, M., Fertig, J. B., & Koob, G. F. (2015) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.12669 · Cited by 330 · cited 1×
“Human laboratory paradigms are proposed as a critical bridge between preclinical studies and large-scale medication trials (McKee, 2009; Perkins and Lerman, 2011; Ray et al., 2010), and are expected to play an important role in treatment development (Litten et al., 2015).”
BackgroundEffect of naltrexone on alcohol “high” in alcoholics
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.4.613 · Cited by 308
Ray, L. A., & Hutchison, K. E. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.9.1069 · Cited by 258
Naltrexone-induced alterations in human ethanol intoxication
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.10.1463 · Cited by 254 · cited 3×
“Indirect support for these potential mechanisms comes from controlled human laboratory investigations, which first emerged shortly following the first naltrexone RCTs (Swift et al., 1994).”
BackgroundInfluentialKing, A. C., Volpicelli, J. R., Frazer, A., & O'Brien, C. P. (1997) · Psychopharmacology · doi:10.1007/s002130050156 · Cited by 227 · cited 1×
“Although other domains of subjective responses—in particular, reductions in perceived stimulation (King et al., 1997; Swift et al., 1994)—are important potential treatment mediators, the fact that most studies measured craving allowed us to focus on arguably the most clinically relevant construct,…”
BackgroundDrobes, D. J., Anton, R. F., Thomas, S. E., & Voronin, K. (2004) · Alcoholism Clinical and Experimental Research · doi:10.1097/01.alc.0000139704.88862.01 · Cited by 140
Anton, R. F., Drobes, D. J., Voronin, K., Durazo-Avizu, R., & Moak, D. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1720-7 · Cited by 135
Developing human laboratory models of smoking lapse behavior for medication screening
McKee, S. A. (2009) · Addiction Biology · doi:10.1111/j.1369-1600.2008.00135.x · Cited by 93 · cited 2×
“The additional possibility of larger effect sizes under experimental conditions is an additional argument for laboratory-based medication screening trials, which can provide a cost-efficient means of medication screening (McKee, 2009; Perkins and Lerman, 2011).”
Background
Cited by
Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial
Hendershot, C. S., Bremmer, M. P., Paladino, M. B., Kostantinis, G., Gilmore, T. A., Sullivan, N. R., Tow, A. C., Dermody, S. S., Prince, M. A., Jordan, R., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2024.4789 · Cited by 287
Self-citationBupropion and naltrexone in methamphetamine use disorder
Trivedi, M. H., Walker, R., Ling, W., dela Cruz, A., Sharma, G., Carmody, T., Ghitza, U. E., Wahle, A., Kim, M., Shores-Wilson, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2020214 · Cited by 281
Mifepristone decreases chronic voluntary ethanol consumption in Rhesus macaques
Jimenez, V. A., Walter, N. A. R., Shnitko, T. A., Newman, N., Diem, K., Vanderhooft, L., Hunt, H., & Grant, K. A. (2020) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.000169 · Cited by 20
Metadata
- Authors
- Hendershot, C. S., Wardell, J. D., Samokhvalov, A. V., & Rehm, J.
- Venue
- Addiction Biology
- Publisher
- Wiley
- Published
- 2016-07-14
- Volume
- 22
- Issue
- 6
- Pages
- 1515-1527
- ISSN
- 1355-6215 (ISSN-L)
- 1369-1600
- OpenAlex
- W2476404151
- Cited by
- 96
- References
- 11
- FWCI
- 6.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.